References in periodicals archive ?
15 Inotuzumab Ozogamicin / CMC-544 Market (USD Million), Long Term Forecast: 2018-2024 (Base Scenario) Figure 5.
AG-858, Aldesleukin , Alemtuzumab, AP23573, Apolizumab, Arsenic trioxide, Atra, Avastin, BAY 43-9006, Bevacizumab, BiovaxID , Bortezomib , CEP-701, Ceplene, Clofarabine, Cloretazine, CMC-544 , Decitabine, Enzastaurin , Epratuzumab, FavId , FK228, Flavopiridol, Gemtuzumab, Genasense, Gvax, IDEC-114 , Imatinib, Marqibo, MyVax, Nelarabine , OSI-461, Pixantrone , PKC412, PTK787, Rituximab, SGN-30, SGN-40 , SU5416, Temsirolimus , Troxacitabine, Valspodar, VELCADE, Xcytrin, Zanolimumab, Zarnestra etc.
Aldesleukin , Apolizumab, Arsenic trioxide, Bevacizumab, BiovaxID, Bortezomib, CMC-544 , Enzastaurin , Epratuzumab, FavId , Flavopiridol, Genasense , IDEC-114 , Marqibo, MyVax, Nelarabine , Pixantrone, SGN-30, SGN-40, Temsirolimus, Zanolimumab.
Inotuzumab Ozogamicin / CMC-544 Sales Forecast, 2013-2018 4.
4-1BBL, 506U78, Actimmune, Ad-IFNg, AlloMune, AMD-3100, Aplidin, ASIbcl, Atragen, Avastin, BCX1777, B-E8, Beta LT, Bexxar, Caelyx, Calsed, Campath, Clofarabine, CMC-544, CpG-7909, Depocyte, Edodekin Alpha, Elsamitrucin, FAVID, Fludara, FR-901228, Ganite, GEMZAR, GENASENSE, GRN163, GTI-2040, GTOP-99, hA20, HMR1275, HSPPC-96, Hu1D10, hum291, HuMax, IDEC-114, IDEC-152, IDIOVAX, Intron A, INX-3280, ISF-154, KiroMAb, LY317615, Lymphocide, Lymphorad131, MDX-060, MGV, Midostaurin, MT103, NIPENT, NOVATRONE, Oncolym, OncoTCS, Ontak, Orathecin Rubitecan, Parlodel, PEGIntron, Porleukin, Pretarget Lymphoma, PRO64553, Product R, Prothecan, Remitogen, Rituxan, SGN-30, SGN-35, T-900607, TH9402, Thalidomid, Trap, TRISENOX, UCN-01, VAXID, VB2-011, VEGF Trap, VELCADE, Zevalin
9 Inotuzumab Ozogamicin / CMC-544 Market (USD MM), Long Term Forecast: 2019-2023 (Base Scenario)
Antitumor Efficacy of a Combination of CMC-544 (Inotuzumab Ozogamicin), a CD22-Targeted Cytotoxic Immunoconjugate of Calicheamicin, and Rituximab against Non-Hodgkin's B-Cell Lymphoma.
CMC-544 CMC-544 is an anti-CD22 antibody linked to calicheamicin, a potent cytoxic drug, using technology developed for the FDA-approved drug Mylotarg.
Among novel targeted cytotoxic antibiotics are biotinylated CBI-bearing CC-1065 analogs, bispecific monoclonal antibodies (MAb), cytotoxic peptide conjugates targeted to their receptors on tumors (AN-215, AN-238, D-26232, C-terminal gastrin heptapeptide-targeted cytotoxics), CMC-544, Davanat-2, HPMA-HA-DOX, immunoliposomes (CA15-3 targeting, anti-HER2/doxorubicin immunoliposomes, EGFr-targeted/epirubicin immunoliposomes, and MCC-465), SGN-15, and vitamin-mediated targeted delivery.